Newsroom
For media inquiries, please contact 340B Health Senior Vice President of Communications Jon Tilton at jon.tilton@340bhealth.org or 202-536-2285.
-
340B HOSPITALS ARE INTEGRAL TO THE EFFORT TO PURSUE HEALTH EQUITY
-
STATEMENT ON NEW DRUG COMPANY LAWSUITS TARGETING THE 340B PROGRAM
-
340B HEALTH AND ALLIES DEMAND THAT MANUFACTURERS DISCONTINUE ILLEGAL DRUG PRICING PRACTICES
-
340B HEALTH BOARD ELECTS TWO NEW MEMBERS
-
Eli Lilly, other Big Pharma firms are making it harder for low-income patients to get discount drugs under federal program, doctors say
-
STATEMENT ON HHS GENERAL COUNSEL’S ADVISORY OPINION ON 340B CONTRACT PHARMACIES
-
Drug Makers Are Pulling Back From a Program to Help the Needy
-
HOSPITALS AND PHARMACISTS FILE LAWSUIT OVER DRUG COMPANIES’ REFUSALS OF 340B DISCOUNTS
-
STATEMENT ON HRSA’S FINAL 340B ADMINISTRATIVE DISPUTE RESOLUTION RULE
-
STATEMENT ON FINALIZED MEDICARE CUTS TO 340B HOSPITALS IN 2021
-
STATEMENT ON NOVO NORDISK CUTTING OFF ACCESS TO 340B PRICING THROUGH COMMUNITY-BASED PHARMACIES
-
Unconscionable Drug Company Efforts Threaten Communities Hit Hardest by COVID-19